La catena delle opzioni mostra i dati chiave delle opzioni azionarie di 2U a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per 2U..

2U (OTC:TWOUQ) Azioni, Catena delle Opzioni

2U Inc provides educational technology services for nonprofit colleges and universities. It builds, delivers, and monitors educational platforms that enable online delivery of degree programs and alternative credentials such as short technical courses. The company provides a cloud-based software-as-a-service platform and various technology-enabled services such as learning technology, live class application monitoring, content development, and marketing, among others that help its clients to reach students globally. It is organized into two reportable business segments: the Degree Program segment and the Alternative Credential segment. The vast majority of revenue comes from the company's Degree Program segment, and most of the company's revenue is earned in the United States.

2U Inc

JP Morgan analyst Mark Strouse downgrades Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) from Overweight to Neutral and lowers the price target from $14 to $7.

News

Downgrades

Price Target

Analyst Ratings

FLNC

JP Morgan Downgrades Fluence Energy to Neutral, Lowers Price Target to $7

Oppenheimer analyst Edward Yang maintains Onto Innovation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTO#NYSE">ONTO</a>) with a Outperform and lowers the price target from $240 to $150.

ONTO

Oppenheimer Maintains Outperform on Onto Innovation, Lowers Price Target to $150

<ul>
<li>Conduit Pharmaceuticals files next generation cocrystal patent for VTAMA&#xAE; (tapinarof) which the Company believes could be a superior asset with both inflammatory and autoimmune prospectives just as the drug approaches 2027 exclusivity expiration, positioning the Company for high-value licensing partnerships. &nbsp;</li>
</ul>
NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 11, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") today announces the filing of two groundbreaking patents for tapinarof (VTAMA&#xAE;), including a dual active cocrystal, pairing the drug currently approved in the US for psoriasis and atopic dermatitis with a complementary drug substance known to address key patient needs in inflammatory skin conditions. The Company anticipates this combination drug approach could offer enhanced patient benefits over existing tapinarof formulations by addressing both therapeutic needs and known side effects, such as pain and itch, which are a known priority to sufferers of these conditions but typically overlooked by standard treatments that focus on the underlying disease alone.

Conduit Pharma Files Next Generation Cocrystal Patent For VTAMA With Enhanced Therapeutic And Market Extension Prospects

Jefferies analyst Roger Song upgrades Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) from Hold to Buy and raises the price target from $1 to $2.

Upgrades

NKTR

Jefferies Upgrades Nektar Therapeutics to Buy, Raises Price Target to $2

Oppenheimer analyst Edward Yang maintains KLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>) with a Outperform and lowers the price target from $850 to $700.

KLAC

Oppenheimer Maintains Outperform on KLA, Lowers Price Target to $700

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said he likes Energy Transfer LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>). The company will release earnings for the first quarter of 2025 on Tuesday, May 6, after <a href="https://www.benzinga.com/quote/ET/earnings">the closing bell</a>.
Cramer also said he likes Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>). &#8220;I'd pull the trigger.&#8221; 
As per the recent news, Snowflake announced on Thursday that it received DOD IL5 Provisional Authorization on AWS GovCloud US-West. The authorization enables the company to offer solutions requiring the highest levels of protection for<a href="https://in.benzinga.com/25/04/44740624/snowflake-achieves-dod-il5-authorization-shares-move-lower-what-you-need-to-know"> Controlled Unclassified Information</a>.
The Mad Money host said this is a &#8220;fantastic chance&#8221; to buy Enterprise Products Partners L.P. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPD#NYSE">EPD</a>).
Supporting his view, JP Morgan analyst Jeremy Tonet maintained Enterprise Products Partners with an Overweight rating on March 27 and raised the price target from $37 to $38.
Cramer said no to Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>), adding that it is losing money.
On the earnings front, Applied Digital will host a conference call on Monday, April 14, to discuss its operations and financial results for the fiscal third quarter.
When asked about Peabody Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTU#NYSE">BTU</a>), Cramer said, &#8220;We got to be careful. It's not going to make us money.&#8221;
Peabody Energy, on Feb. 6, reported mixed fourth-quarter financial results.
Price Action:
<ul>
<li>Energy Transfer shares fell 4.6% to settle at $15.91 on Thursday.</li>
<li>Snowflake shares declined 4.4% to close at $144.45 during the session.</li>
<li>Enterprise Products Partners&#8217; shares fell 2.5% to settle at $28.95.</li>
<li>Peabody Energy shares dipped 8.4% to close at $11.23 on Thursday.</li>
<li>Applied Digital shares dipped 7.1% to settle at $5.13 on Thursday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44734419/top-2-real-estate-stocks-that-may-keep-you-up-at-night-this-month">Top 2 Real Estate Stocks That May Keep You Up At Night This Month</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Markets

Media

Trading Ideas

APLD

SNOW

Jim Cramer Likes Energy Transfer And Snowflake, Says Applied Digital Is Losing Money

Jefferies analyst Andrew Andersen downgrades Skyward Specialty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKWD#NASDAQ">SKWD</a>) from Buy to Hold and lowers the price target from $62 to $59.

SKWD

Jefferies Downgrades Skyward Specialty to Hold, Lowers Price Target to $59

INTA

Intapp To Acquire TermSheet; Financial Terms Not Disclosed

PSEC

QCCO

Prospect Capital Corporation To Acquire QC Holdings For $2/Share In Cash

Goldman Sachs Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) will release earnings results for the first quarter, before the <a href="https://www.benzinga.com/quote/GS/earnings">opening bell on Monday, April 14.</a>
Analysts expect the bank to report quarterly earnings at $12.35 per share, up from $11.58 per share in the year-ago period. Goldman Sachs projects to report quarterly revenue at $14.81 billion, compared to $14.21 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Tuesday, JMP Securities analyst Devin Ryan maintained Goldman Sachs with a Market Outperform rating and lowered the price target from $625 to $600.
With the recent buzz around Goldman Sachs, some investors may be eyeing potential gains from the company's dividends too. Currently, Goldman Sachs offers an annual dividend yield of 2.45%. That&#8217;s a quarterly dividend of $3.00 per share ($12.00 annually).  
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $244,900 or around 500 shares. For a more modest $100 per month or $1,200 per year, you would need $48,980 or around 100 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($12.00 in this case). So, $6,000 / $12.00 = 500 ($500 per month), and $1,200 / $12.00 = 100 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
GS Price Action: Shares of Goldman Sachs fell 5.2% to close at $489.80 on Thursday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44734419/top-2-real-estate-stocks-that-may-keep-you-up-at-night-this-month">Top 2 Real Estate Stocks That May Keep You Up At Night This Month</a></li>
</ul>
Image: Shutterstock

Earnings

How To Earn $500 A Month From Goldman Sachs Stock Ahead Of Q1 Earnings

The Board of Directors of CSW Industrials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSWI#NASDAQ">CSWI</a>) today declared a regular quarterly cash dividend of $0.27 per share. This represents an increase of $0.03 per share, or approximately 12.5%, as compared to the paid dividend in the prior quarter. The dividend is payable on May 9, 2025, to shareholders of record as of the close of business on April 25, 2025.

Dividends

CSWI

CSW Industrials Increases Quarterly Dividend From $0.24 To $0.27 Per Share

Jefferies analyst Andrew Andersen upgrades Everest Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EG#NYSE">EG</a>) from Hold to Buy and raises the price target from $376 to $415.

Jefferies Upgrades Everest Group to Buy, Raises Price Target to $415

Economics

PPI ex. Food/Energy/Transport (YoY) (Mar) +3.4%; +3.5% Prior

Macro Economic Events

Econ #s

USA Core PPI (MoM) For March -0.1% Vs 0.3% Est.; 0.1% Prior

Macro Notification

General

USA PPI (MoM) For March -0.4% Vs 0.2% Est.; 0.1Prior

US PPI (YoY) (Mar) +2.7% vs +3.3% Est.

Baird analyst Craig Kennison maintains CarMax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMX#NYSE">KMX</a>) with a Outperform and lowers the price target from $95 to $90.

Baird Maintains Outperform on CarMax, Lowers Price Target to $90

Jefferies analyst Matthew Hurwit initiates coverage on Blue Owl Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OBDC#NYSE">OBDC</a>) with a Buy rating and announces Price Target of $16.

Initiation

OBDC

Jefferies Initiates Coverage On Blue Owl Capital with Buy Rating, Announces Price Target of $16

On CNBC's <a href="https://www.cnbc.com/video/2025/04/10/final-trades-vertex-robinhood-palo-alto-and-crowdstrike.html">&#8220;Halftime Report Final Trades</a>,&#8221; Joshua Brown of Ritholtz Wealth Management picked CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>).
On Wednesday, CrowdStrike announced an expansion of its partnership with Alphabet Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) Google Cloud to enable end-to-end security for AI innovation with the company's Falcon Cloud Security platform.
Don't forget to check out our<a href="https://www.benzinga.com/premarket/"> premarket coverage here</a>
Brenda&nbsp;Vingiello of Sand Hill Global Advisors named Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), saying the first non-opioid pain medication <a href="https://www.benzinga.com/quote/VRTX/earnings">will be a game changer</a>.
Vertex Pharmaceuticals will report its first-quarter financial results on Monday, May 5, after the closing bell.
Bryn Talkington of Requisite Capital Management picked Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) as her final trade.
On the earnings front, Robinhood Markets will release its first quarter financial results on Wednesday, April 30, after the closing bell. Analysts expect the company to report quarterly earnings at 37 cents per share on revenue of $909.41 million.
Stephanie Link of Hightower named Palo Alto Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>), a cybersecurity stock.
Supporting her view, HSBC analyst Stephen Bersey, on Thursday, upgraded Palo Alto Networks from Reduce to Hold and announced a $156 price target.
Price Action:
<ul>
<li>Vertex Pharmaceuticals shares fell 1.4% to close at $475.49 on Thursday.</li>
<li>Robinhood shares dipped 4% to close at $40.51 during Thursday's session.</li>
<li>CrowdStrike shares fell 2.5% to close at $368.61 on Thursday.</li>
<li>Palo Alto Networks fell 2.8% to settle at $168.27 during Thursday's session.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44734419/top-2-real-estate-stocks-that-may-keep-you-up-at-night-this-month">Top 2 Real Estate Stocks That May Keep You Up At Night This Month</a></li>
</ul>
Image: Shutterstock

CRWD

GOOG

HOOD

PANW

VRTX

CrowdStrike, Robinhood, Palo Alto Networks And A Health Care Stock On CNBC's 'Final Trades'

Baird analyst Joe Vruwink maintains Certara (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>) with a Neutral and raises the price target from $9 to $13.

Comments

2U

2U (TWOUQ) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO